Supernus, Inc.

Supernus, Inc.

SUPN

$28.21

Updated: 05/11/2026, 09:20:37

Market Cap
$1.64B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US

No historical data available

Company Profile

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.

USD
NASDAQ
CEO: Jack A. Khattar
Employees: 778
https://www.supernus.com
Asset Summaries
Latest generated summaries for SUPN

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for SUPN.
Share price
$28.21
Market cap
$1.64B
Exchange
NASDAQ
Currency
USD
CEO
Jack A. Khattar
Employees
778
IPO date
30/04/2012
Beta
0.5206186
Last dividend
$0.00
Day range
$26.74 – $28.99
52-week range
$26.74 – $44.31
1-day performance
0.21%
1-year performance
5.50%
Current drawdown (1Y)
-36.33%
CIK
0001356576
CUSIP
45579U109
ISIN
US45579U1097
Created
07/12/2025, 14:26:05
Last update
05/11/2026, 09:20:37

Track Supernus, Inc. with an AI analyst

See which prediction-market events move SUPN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.